Sickle Cell Disease (SCD) is a devastating genetic hematological disorder leading to significant morbidity and mortality. A major complication is skeletal malformation in children leading to severe systemic skeletal deterioration (osteoporosis). Our goal is to apply nanotechnology to remedy the inflammatory environment and skeletal aberrations associated with SCD using silica based 50 nm nanoparticles which suppress NF-κB signaling, a pro-inflammatory pathway, and stimulate bone accretion in healthy mice.